Table 4 Comparison between positive and negative hepatic steatosis patients according to the presence of LI-RADS major and ancillary features
Characteristics | Total | Hepatic steatosis | p value | ||
|---|---|---|---|---|---|
Positive | Negative | ||||
Major HCC features | |||||
Non-rim APHE | Early | 48 (52.2%) | 14 (31.1%) | 34 (72.3%) | 0.000 |
Late | 44 (47.8%) | 31 (68.9%) | 13 (27.7%) | ||
Non-peripheral “washout” | No | 5 (5.4%) | 4 (8.9%) | 1 (2.1%) | 0.175 |
Portal | 42 (45.7%) | 17 (37.8%) | 25 (53.2%) | ||
Delayed | 45 (48.9%) | 24 (53.3%) | 21 (44.7%) | ||
Enhancing capsule | 51 (55.4%) | 17 (37.8%) | 34 (72.3%) | 0.001 | |
Size (mm) | < 50 | 62 (67.4%) | 37 (82.2%) | 25 (53.2%) | 0.003 |
50 or more | 30 (32.6%) | 8 (17.8%) | 22 (46.8%) | ||
Threshold growth | 17 (18.5%) | 11 (24.4%) | 6 (12.8%) | 0.149 | |
Ancillary features favoring malignancy | |||||
Corona enhancement | 8 (8.7%) | 3 (6.7%) | 5 (10.6%) | 0.714 | |
Threshold growth | 14 (15.2%) | 10 (22.2%) | 4 (8.5%) | 0.067 | |
Mild–moderate T2 hyperintensity | 74 (80.4%) | 32 (71.1%) | 42 (89.4%) | 0.027 | |
Restricted diffusion | 70 (76.1%) | 34 (75.6%) | 36 (76.6%) | 0.907 | |
Fat sparing in solid mass | 5 (5.4%) | 5 (11.1%) | 0 (0%) | 0.025 | |
Ancillary features favoring HCC | |||||
Non-enhancing “capsule” | 7 (7.6%) | 7 (15.6%) | 0 (0%) | 0.005 | |
Nodule-in-nodule architecture | 6 (6.5%) | 2 (4.4%) | 4 (8.5%) | 0.677 | |
Mosaic architecture | 9 (9.8%) | 3 (6.7%) | 6 (12.8%) | 0.486 | |
Fat in mass, more than adjacent liver | 31 (33.7%) | 7 (15.6%) | 24 (51.1%) | 0.000 | |
Blood products in mass | 6 (6.5%) | 1 (2.2%) | 5 (10.6%) | 0.204 | |